{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:36:33Z","timestamp":1788456993698,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["P10307"],"award-info":[{"award-number":["P10307"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>To evaluate dosimetry, dose\u2013response and dose-toxicity relationships for holmium-166 (<jats:sup>166<\/jats:sup>Ho) radioembolisation in patients with hepatocellular carcinoma (HCC).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Thirty-one patients with hepatocellular carcinoma were included in the HEPAR Primary study (NCT03379844, registered on December 20th, 2017) and underwent <jats:sup>166<\/jats:sup>Ho-microspheres radioembolisation. Linear mixed models assessed the association between tumour absorbed doses and response based on mRECIST both on tumour and patient level. Preliminary tumour absorbed dose thresholds were estimated based on predictive value. Linear regression models assessed the association between non-tumour absorbed dose and Common Terminology Criteria for Adverse Events version 4.03.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Median tumour absorbed dose (tumour level) was 95.5 Gy (range 44\u2014332 Gy). Median non-tumour absorbed dose based on whole liver volume was 19 Gy (range 3 \u2013 48 Gy) and based on target liver volume was 30 Gy (range 13 \u2013 54 Gy). There was a significant association between non-tumour absorbed dose and toxicity. Tumours with partial response\/complete response (PR\/CR, responders) received a 41% higher absorbed dose than tumours with progressive disease\/stable disease (PD\/SD, non-responders) (95%CI: 2%-93%, <jats:italic>p<\/jats:italic>\u2009=\u20090.04). A predictive value of 90% for tumour response was observed at a tumour absorbed dose threshold of 155 Gy, 100% predictive value was achieved at 184.5 Gy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This study confirms a positive relationship between tumour absorbed dose and response and between non-tumour absorbed dose and toxicity. Dose thresholds found in this study can serve as a basis for personalized dosimetry in HCC patients treated with <jats:sup>166<\/jats:sup>Ho-microspheres.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00259-024-06940-2","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T08:39:27Z","timestamp":1730191167000},"page":"993-1003","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Holmium-166 radioembolisation dosimetry in HCC"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0501-9427","authenticated-orcid":false,"given":"Margot T. M.","family":"Reinders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8824-8697","authenticated-orcid":false,"given":"Arthur J. A. T.","family":"Braat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4034-5444","authenticated-orcid":false,"given":"Karel J.","family":"van Erpecum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joep","family":"de Bruijne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5167-4027","authenticated-orcid":false,"given":"Rutger C. G.","family":"Bruijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4280-4210","authenticated-orcid":false,"given":"Dave","family":"Sprengers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"de Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-2258","authenticated-orcid":false,"given":"Erik","family":"Vegt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3558-1039","authenticated-orcid":false,"given":"Jan N. M.","family":"IJzermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3903-4024","authenticated-orcid":false,"given":"Sjoerd G.","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4902-9790","authenticated-orcid":false,"given":"Marnix G. E. H.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4735-655X","authenticated-orcid":false,"given":"Maarten L. J.","family":"Smits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"key":"6940_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04460-y","author":"MLJ Smits","year":"2019","unstructured":"Smits MLJ, Dassen MG, Prince JF, Braat A, Beijst C, Bruijnen RCG, et al. The superior predictive value of (166)Ho-scout compared with (99m)Tc-macroaggregated albumin prior to (166)Ho-microspheres radioembolization in patients with liver metastases. Eur J Nucl Med Mol Imaging. 2019. https:\/\/doi.org\/10.1007\/s00259-019-04460-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6940_CR2","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/s1470-2045(12)70334-0","volume":"13","author":"MLJ Smits","year":"2012","unstructured":"Smits MLJ, Nijsen JFW, van den Bosch MAAJ, Lam MGEH, Vente MAD, Mali WPTM, et al. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study. Lancet Oncol. 2012;13:1025\u201334. https:\/\/doi.org\/10.1016\/s1470-2045(12)70334-0.","journal-title":"Lancet Oncol"},{"key":"6940_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/s2468-1253(20)30290-9","volume":"6","author":"E Garin","year":"2021","unstructured":"Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, de Baere T, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6:17\u201329. https:\/\/doi.org\/10.1016\/s2468-1253(20)30290-9.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"6940_CR4","doi-asserted-by":"publisher","first-page":"272","DOI":"10.2967\/jnumed.120.243832","volume":"62","author":"C van Roekel","year":"2021","unstructured":"van Roekel C, Bastiaannet R, Smits MLJ, Bruijnen RC, Braat A, de Jong H, et al. Dose-Effect Relationships of (166)Ho Radioembolization in Colorectal Cancer. J Nucl Med. 2021;62:272\u20139. https:\/\/doi.org\/10.2967\/jnumed.120.243832.","journal-title":"J Nucl Med"},{"key":"6940_CR5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.255745","author":"AA Alsultan","year":"2021","unstructured":"Alsultan AA, van Roekel C, Barentsz MW, Smits MLJ, Kunnen B, Koopman M, et al. Dose-response and dose-toxicity relationships for yttrium-90 glass radioembolization in patients with colorectal cancer liver metastases. J Nucl Med. 2021. https:\/\/doi.org\/10.2967\/jnumed.120.255745.","journal-title":"J Nucl Med"},{"key":"6940_CR6","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.263823","author":"MTM Reinders","year":"2022","unstructured":"Reinders MTM, van Erpecum KJ, Smits MLJ, Braat A, de Bruijne J, Bruijnen RCG, et al. Safety and efficacy of holmium-166 radioembolization in hepatocellular carcinoma - the HEPAR Primary study. J Nucl Med. 2022. https:\/\/doi.org\/10.2967\/jnumed.122.263823.","journal-title":"J Nucl Med"},{"key":"6940_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52\u201360. https:\/\/doi.org\/10.1055\/s-0030-1247132.","journal-title":"Semin Liver Dis"},{"key":"6940_CR8","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.29086","volume":"67","author":"JK Heimbach","year":"2018","unstructured":"Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358\u201380. https:\/\/doi.org\/10.1002\/hep.29086.","journal-title":"Hepatology"},{"key":"6940_CR9","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1053\/j.semnuclmed.2019.01.006","volume":"49","author":"E Garin","year":"2019","unstructured":"Garin E, Rolland Y, Edeline J. (90)Y-loaded microsphere SIRT of HCC patients with portal vein thrombosis: high clinical impact of 99mTc-MAA SPECT\/CT-based dosimetry. Semin Nucl Med. 2019;49:218\u201326. https:\/\/doi.org\/10.1053\/j.semnuclmed.2019.01.006.","journal-title":"Semin Nucl Med"},{"key":"6940_CR10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40658-018-0221-z","volume":"5","author":"R Bastiaannet","year":"2018","unstructured":"Bastiaannet R, Kappadath SC, Kunnen B, Braat A, Lam M, de Jong H. The physics of radioembolization. EJNMMI Phys. 2018;5:22. https:\/\/doi.org\/10.1186\/s40658-018-0221-z.","journal-title":"EJNMMI Phys"},{"key":"6940_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40658-020-0280-9","volume":"7","author":"R van Rooij","year":"2020","unstructured":"van Rooij R, Braat AJAT, de Jong HWAM, Lam MGEH. Simultaneous 166Ho\/99mTc dual-isotope SPECT with Monte Carlo-based downscatter correction for automatic liver dosimetry in radioembolization. EJNMMI Physics. 2020;7:13. https:\/\/doi.org\/10.1186\/s40658-020-0280-9.","journal-title":"EJNMMI Physics"},{"key":"6940_CR12","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2307\/2533958","volume":"53","author":"NA Obuchowski","year":"1997","unstructured":"Obuchowski NA. Nonparametric analysis of clustered ROC curve data. Biometrics. 1997;53:567\u201378.","journal-title":"Biometrics"},{"key":"6940_CR13","doi-asserted-by":"publisher","first-page":"6455","DOI":"10.1002\/sim.3418","volume":"27","author":"G Heinze","year":"2008","unstructured":"Heinze G, Dunkler D. Avoiding infinite estimates of time-dependent effects in small-sample survival studies. Stat Med. 2008;27:6455\u201369. https:\/\/doi.org\/10.1002\/sim.3418.","journal-title":"Stat Med"},{"key":"6940_CR14","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1007\/s00259-021-05600-z","volume":"49","author":"M Weber","year":"2022","unstructured":"Weber M, Lam M, Chiesa C, Konijnenberg M, Cremonesi M, Flamen P, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2022;49:1682\u201399. https:\/\/doi.org\/10.1007\/s00259-021-05600-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6940_CR15","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s00330-012-2648-2","volume":"23","author":"GH van de Maat","year":"2013","unstructured":"van de Maat GH, Seevinck PR, Elschot M, Smits ML, de Leeuw H, van Het Schip AD, et al. MRI-based biodistribution assessment of holmium-166 poly(L-lactic acid) microspheres after radioembolisation. Eur Radiol. 2013;23:827\u201335. https:\/\/doi.org\/10.1007\/s00330-012-2648-2.","journal-title":"Eur Radiol"},{"key":"6940_CR16","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1007\/s00259-015-3059-9","volume":"42","author":"KP Willowson","year":"2015","unstructured":"Willowson KP, Tapner M, Bailey DL. A multicentre comparison of quantitative (90)Y PET\/CT for dosimetric purposes after radioembolization with resin microspheres\u202f: The QUEST Phantom Study. Eur J Nucl Med Mol Imaging. 2015;42:1202\u201322. https:\/\/doi.org\/10.1007\/s00259-015-3059-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6940_CR17","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.2967\/jnumed.109.074559","volume":"51","author":"H Ahmadzadehfar","year":"2010","unstructured":"Ahmadzadehfar H, Sabet A, Biermann K, Muckle M, Brockmann H, Kuhl C, et al. The significance of 99mTc-MAA SPECT\/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment. J Nucl Med. 2010;51:1206\u201312. https:\/\/doi.org\/10.2967\/jnumed.109.074559.","journal-title":"J Nucl Med"},{"key":"6940_CR18","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1007\/s00259-014-2784-9","volume":"41","author":"M Elschot","year":"2014","unstructured":"Elschot M, Nijsen JFW, Lam MGEH, Smits MLJ, Prince JF, Viergever MA, et al. (\u2079\u2079m)Tc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with 1\u2076\u2076Ho-microspheres. Eur J Nucl Med Mol Imaging. 2014;41:1965\u201375. https:\/\/doi.org\/10.1007\/s00259-014-2784-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6940_CR19","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1007\/s00259-019-04588-x","volume":"47","author":"AS Pasciak","year":"2020","unstructured":"Pasciak AS, Abiola G, Liddell RP, Crookston N, Besharati S, Donahue D, et al. The number of microspheres in Y90 radioembolization directly affects normal tissue radiation exposure. Eur J Nucl Med Mol Imaging. 2020;47:816\u201327. https:\/\/doi.org\/10.1007\/s00259-019-04588-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6940_CR20","unstructured":"Sirtex. Sirtex FLEXdose Delivery Program. Australia: MIM Software; 2021. https:\/\/www.sirtex.com\/media\/cntobgwe\/flexdose-delivery-programme-brochure-emea-apm-emea-012-07-20-v4.pdf. Accessed 10 Jun 2024."},{"key":"6940_CR21","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1007\/s00259-021-05340-0","volume":"48","author":"J Roosen","year":"2021","unstructured":"Roosen J, Klaassen NJM, Westlund Gotby LEL, Overduin CG, Verheij M, Konijnenberg MW, et al. To 1000 Gy and back again: a systematic review on dose-response evaluation in selective internal radiation therapy for primary and secondary liver cancer. Eur J Nucl Med Mol Imaging. 2021;48:3776\u201390. https:\/\/doi.org\/10.1007\/s00259-021-05340-0.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06940-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-06940-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06940-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T04:27:59Z","timestamp":1737520079000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-06940-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["6940"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-06940-2","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,29]]},"assertion":[{"value":"7 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This clinical study was approved by the Medical Ethics Committee of University Medical Centre Utrecht and Erasmus Medical Centre and by the institutional radiation protection committee. Furthermore, this study was performed in concordance with Good Clinical Practice and the declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided written, informed consent before undergoing any study-specific activity.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Margot Reinders-Hut is currently employed by Genmab B.V., acted as a speaker for Boston Scientific. Marnix Lam acts as a consultant for Terumo, Quirem Medical and Boston Scientific, receives research support from Terumo, Quirem Medical and Boston Scientific. Maarten Smits and Arthur Braat are consultants for Terumo. The department of Radiology and Nuclear Medicine of the University Medical Centre Utrecht receives royalty payments from Quirem Medical.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}